News

Ceres Nanosciences Receives $1.4M From NIH RADx Initiative to Add Five Additional Wastewater-Based Epidemiology Centers of Excellence

MANASSAS, Virginia – Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing today that it is expanding the network of wastewater-based epidemiology centers of excellence that was established with support from the National Institutes of Health (NIH) RADx® initiative. With a new $1.4 million award from the NIH, Ceres will identify and establish five additional centers of excellence to join the existing network of 16 sites comprising public health labs, non-profit labs, university labs, and commercial testing labs in 14 states. Ceres also will support the verification of SARS-CoV-2 genotyping from wastewater samples and the addition of this capacity to a subset of the centers of excellence.

coemap.png

Each new center of excellence will receive the materials and on-site training to implement an automated Nanotrap® particle protocol, which enables same-day delivery of wastewater testing results for over 100 samples per day. Extracted nucleic acids from this automated protocol are compatible with multiple nucleic acid detection methods, including reverse transcription-quantitative polymerase chain reaction, reverse transcription-droplet digital PCR, reverse transcription digital PCR, and genomic sequencing.

“The United States is demonstrating global leadership in wastewater-based epidemiology through public-private partnerships like this,” said Robbie Barbero, Ph.D., Chief Business Officer at Ceres Nanosciences. “I am very proud that Ceres has once again been recognized by the U.S. government for our innovative technology and collaborative approach to advancing this field.”

Centers are expected to share data and results with local, state, Tribal, and Federal public health decision makers and to participate in the CDC National Wastewater Surveillance System. Each new center will be selected based on its ability to utilize the expanded testing capacity to extend services into underserved and underprivileged communities and to balance the geographic reach of the network.

Read more here

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the